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Abstract
Background: The association of peripapillary retinal nerve fibre layer (pRNFL) and ganglion cell-inner
plexiform layer (GCIPL) thickness with neurodegeneration in multiple sclerosis (MS) is well estab-
lished. The relationship of the adjoining inner nuclear layer (INL) with inflammatory disease activity is
less well understood.
Objective: The objective of this paper is to investigate the relationship of INL volume changes with
inflammatory disease activity in MS.
Methods In this longitudinal, multi-centre study, optical coherence tomography (OCT) and clinical data
(disability status, relapses and MS optic neuritis (MSON)) were collected in 785 patients with MS
(68.3% female) and 92 healthy controls (63.4% female) from 11 MS centres between 2010 and 2017
and pooled retrospectively. Data on pRNFL, GCIPL and INL were obtained at each centre.
Results: There was a significant increase in INL volume in eyes with new MSON during the study
(N¼ 61/1562, b¼ 0.01mm3, p< .001). Clinical relapses (other than MSON) were significantly associ-
ated with increased INL volume (b¼ 0.005, p¼ .025). INL volume was independent of disease pro-
gression (b¼ 0.002mm3, p¼ .474).
Conclusion: Our data demonstrate that an increase in INL volume is associated with MSON and the
occurrence of clinical relapses. Therefore, INL volume changes may be useful as an outcome marker for
inflammatory disease activity in MSON and MS treatment trials.
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Introduction
Thinning of the inner retinal layers, as observed with
the use of optical coherence tomography (OCT), is a
common finding in multiple sclerosis (MS)
patients.1 Retinal OCT has been suggested as a
structural imaging biomarker for neuroaxonal degen-
eration, as reduced thickness of both the peripapil-
lary retinal nerve fibre layer (pRNFL, consisting of
axons) and the combined thickness of the ganglion
cell layer and inner plexiform layer (GCIPL, consist-
ing of mainly ganglion cells) have shown to be asso-
ciated with grey and white matter atrophy in patients
with MS.2–6 Although the association of pRNFL and
GCIPL thickness with neurodegeneration in MS is
well established, a more complex situation is
observed for the adjoining inner nuclear layer
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(INL). A histological study demonstrated that the
INL, representing a neuronal network of bipolar,
amacrine and horizontal cells, shows signs of atro-
phy but the presence of inflammatory cells was also
described.7 Nevertheless, the INL seems not to be
susceptible to retrograde degeneration caused by
MS-related optic neuritis (MSON), as it does not
show the extensive neuro-axonal injury in eyes
with MSON as observed in the pRNFL and
GCIPL.1,8 Rather than reflecting neurodegeneration
like the innermost pRNFL and GCIPL, the INL may
rather be a biomarker for inflammatory processes. In
2012, Gelfand et al. first described the presence of
microcystic macular oedema (MMO) in the INL and
the relationship with disability.9 Furthermore, a ret-
rospective study by Saidha and colleagues reported
that increased thickness of the combined INL and
outer plexiform layer (OPL) was associated with dis-
ease activity in MS.10 More recently, Knier et al.
reported that successful use of disease-modifying
treatment (DMT) is associated with sustained reduc-
tion of INL volume,11 suggesting that the INL could
serve as a biomarker to monitor central nervous
system inflammation. Therefore, the aim of this
study was to investigate the relationship of INL
volume changes over time with local and global
inflammatory disease activity in a large cohort of
patients with MS.
Methods
Study design and participants
We used longitudinal data from the International
Multiple Sclerosis Visual System Consortium
(IMSVISUAL) database (www.imsvisual.org).
Patients were recruited from 11 centres in the
Netherlands (Amsterdam N¼ 165), Germany (Berlin
N¼ 81, Du¨sseldorf N¼ 15, Munich (Universit€at
Mu¨nchen) N¼ 11, Munich (Technische Universit€at
Mu¨nchen) N¼ 169), Kuwait (Kuwait-City N¼ 98),
Spain (Barcelona CEMCAT N¼ 39, Barcelona
IDIBAPS N¼ 69), Italy (Milan N¼ 56), the United
States (New York City N¼ 10) and France (Lille
N¼ 72). Healthy control individuals (HCs) were
recruited from three centres (Amsterdam N¼ 41,
Munich N¼ 17 and Berlin N¼ 34). All patients
and HCs participated in local observational studies
and provided written informed consent for participa-
tion in their respective studies. Data were pooled
retrospectively. All data from reported and ongoing
cohort studies at MS centres were stored in the
IMSVISUAL repository. The raw dataset is avail-
able from IMSVISUAL on request.
Data were collected between 2010 and 2017. MS
patients were included if they were between ages
16 and 80 years, and had a diagnosis of clinically
isolated syndrome or MS (including relapsing–
remitting (RR), secondary progressive (SP) and pri-
mary progressive (PP) subtypes) according to the
revised 2010 McDonald Criteria.12 HCs were includ-
ed if they were between ages 18 and 80 years and
had no history of any neurological disease or oph-
thalmologic reason for retinal pathology. Regarding
the OCT assessments, individuals were included if
they had at least two OCT measurements (baseline
and at least one follow-up) with INL volume avail-
able for at least one eye (minimum follow-up period
of six months). Patients were excluded if they had
experienced symptomatic MSON within six months
preceding the OCT assessment (baseline or follow-
up), or if history of MSON was ambiguous or
unknown. Inclusion and exclusion of individuals is
shown in the flowchart in Figure 1.
OCT
Retinal OCT was performed at each centre by use of
spectral-domain OCT with Spectralis (Heidelberg
Engineering, Heidelberg, Germany, N¼ 10) or
OCT-2000 (Topcon Corp, Itabashi, Japan, N¼ 1).
Data on the INL and GCIPL volume (mm3) in the
macular area were acquired using a macular volume
scan centred on the fovea, using a 6mm ring area.
Data on global pRNFL thickness (mm) were obtained
using a 12-degree ring scan (corresponding to a
3.4mm diameter) manually placed around the optic
disc. At each centre, automated segmentation of
OCT scans and quality control (including the assess-
ment whether eyes had signs of MMO) were per-
formed.13,14 Importantly, the scanning device and
protocols were kept identical for all longitudinal
measurements within each centre.15
Clinical and ophthalmological outcome measures
Demographic data included data on sex, age at base-
line and disease duration (from disease onset).
Clinical data were collected longitudinally and
included MS subtype, occurrence of relapses
between visits, Expanded Disability Status Scale
(EDSS) score, history of previous MSON and occur-
rence of new episodes of MSON between visits,
presence of MMO and use of DMT. The assessment
of history of symptomatic MSON (based on medical
history, according to a standard protocol),16 EDSS
score and data on clinical relapses were provided by
the individual centres.
Importantly, given the longitudinal design of this
study, we made a clear distinction between episodes
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of MSON before the study (referred to as ‘pre-study
MSON’) and episodes of MSON during the follow-
up of the study (referred to as ‘MSON during
follow-up’).
EDSS assessment was performed by a certified
examiner and in the absence of acute relapses.
Disability progression was defined by an increase
in EDSS score of 1.0 point in case EDSS score
was less than 5.5 at baseline, or an increase of 0.5
if EDSS score was 5.5 or greater at baseline. This
approach is consistent with previous IMSVISUAL
collaborative projects.17
Statistical analyses
Annualised changes in retinal layer thickness or
volume were calculated for every follow-up period.
Subsequently, the annualised change scores were
averaged over the complete observation period,
resulting in one average annualised rate of change
for every eye. All analyses were therefore performed
on eye level, using generalised estimation equation
(GEE) models with a correlation matrix structure
that treats the eye measurements as exchangeable
to adjust for intra-subject inter-eye dependency.15
All GEE models were additionally adjusted for rel-
evant confounders (baseline OCT value, pre-study
episodes of MSON, disease duration, use of DMT)
as indicated. Figures showing longitudinal changes
in retinal layer thickness were produced using rela-
tive annualised change scores (i.e. baseline was set
as 100%).
Regarding the associations between annualised
change in retinal thickness and the occurrence of
relapses or disease progression, all eyes with a
history of MSON were excluded. Short-term
effects (clinical event and retinal change assessed
within same follow-up period) as well as long-
term effects (time-lag analyses, clinical event
between baseline and first follow-up visit and
change in retinal layer thickness between first
and second follow-up visit) were investigated.
Consequently, only individuals with at least three
visits were included in these analyses. All analyses
were adjusted for their respective baseline retinal
layer thickness.
Correlations between the different layers were cal-
culated with standardised regression coefficients in
GEE models and are therefore also adjusted for
inter-eye dependency. Statistical analyses were per-
formed using SPSS V.22.0 (IBM Corp, Armonk,
NY, USA) and Stata V.14.1 (StataCorp LP,
College Station, TX, USA) with a two-sided statis-
tical significance level of .05.
Figure 1. Flowchart of study design. Of the 903 individuals in the initial database, 785 patients and 92 healthy controls
were included in this study. All participants had at least two visits, and a subset also had a third or fourth visit.
Longitudinal data on inner nuclear layer (INL) and ganglion cell-inner plexiform layer (GCIPL) volume (at least two
visits, minimum follow-up >6 months) was available for all included individuals and peripapillary retinal nerve fibre
layer (pRNFL) for 765 patients and 91 healthy controls.
IMSVISUAL: International Multiple Sclerosis Visual System Consortium; MS: multiple sclerosis; MSON: multiple
sclerosis optic neuritis.
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Results
Baseline
In total, 1570 eyes from 785 MS patients (68.3%
female) and 184 eyes from 92 HCs (63.4%
female) were included (Figure 1). MS patients had
a median disease duration of 6.4 years (interquartile
range (IQR) 1.9–15.0). The majority of patients
(80.3%) had an RR disease course. More than half
of all patients (N¼ 419, 53.4%) had never experi-
enced a clinically confirmed MSON before baseline.
Of all patients with a history of at least one con-
firmed episode of pre-study MSON (N¼ 366), 281
(77%) patients had unilateral MSON and 85 (23%)
a history of MSON in both eyes (not necessarily
simultaneously). MMO was present in 2.4% of
patients (15/638) and in 1.4% (18/1275) of eyes.
An overview of the baseline characteristics is
shown in Table 1.
At baseline, MS patients showed significantly higher
INL volume compared with HCs (difference of
0.02mm3, p¼ .018) and lower GCIPL volume and
pRNFL thickness (difference of –0.18mm3 and –4.4
mm, respectively, p< .001 for both comparisons).
Eyes with pre-study episodes of MSON showed a
higher INL volume compared with eyes without
(0.99 0.08mm3 and 0.97 0.08mm3, respective-
ly, p¼ .001), whereas GCIPL volume and
pRNFL thickness alike were lower in eyes with
pre-study MSON compared with eyes without
(Table 2).
Change over time in INL, GCIPL and pRNFL
thickness and the effect of MSON
The median follow-up duration was 2.1 years (range,
0.5 to 5.2 years) for MS patients and 2.0 years
(range, 0.6 to 4.6 years) for HCs. When all eyes of
MS patients were analysed together, the INL showed
Table 1. Baseline characteristics.
All participants
N¼ 785
Healthy controls
(N¼ 92)
Sex (female, N, %) 536 (68.3%) 59 (63.4%)
Age (y) 41.0 (12.6) 43.4 (11.5)
Disease duration (y, median (IQR)) 6.4 (1.9–15.0)
EDSS (median (IQR)) 2.0 (1.0–3.0)
Disease type
CIS 45 (5.7%)
RRMS 630 (80.3%)
SPMS 74 (9.4%)
PPMS 36 (4.6%)
MSON before baseline, N (%)
No previous MSON 419 (53.4%)
MSON
Unilateral MSON 281 (35.8%)
Bilateral MSON 85 (10.8%)
MMO before baseline (N¼ 638)
MMO– 623 (97.6%)
MMOþ 15 (2.4%)
Disease-modifying treatment at moment of baseline (N¼ 743)
None 343 (46.2%)
Interferon beta 172 (23.2%)
Glatiramer acetate 72 (9.7%)
Natalizumab 61 (8.3%)
Fingolimod 53 (7.1%)
Dimethyl fumarate 20 (2.7%)
Othera 21 (2.8%)
CIS: clinically isolated syndrome; EDSS: Expanded Disability Status Scale; IQR: interquartile range, reported as 25th
and 75th percentile; MMO: microcystic macular oedema; MSON: multiple sclerosis–related optic neuritis; PP: pri-
mary progressive; RR: relapsing remitting; SP: secondary progressive.
aRituximab, teriflunomide, azathioprine, mitoxantrone, cyclophosphamide, alemtuzumab and mycophenolate mofetil.
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a non-significant average annualised rate of change
of –0.0003mm3 (p¼ .553, Figure 2(a)). HCs also
showed no significant change (annualised rate of
change 0.006mm3, p¼ .245).
Regarding the effect of MSON, there was a clear
difference between pre-study MSON (i.e. before
the baseline OCT assessment) and MSON occurring
during the follow-up period. Pre-study MSON did
not affect the rate of change in INL thickness signif-
icantly. Eyes with and without pre-study MSON
showed similar rates of change of the INL
(b¼ 0.001, p¼ .219). In contrast, any episode of
MSON during the observation period strongly
affected INL volume. In eyes with MSON during
follow-up (N¼ 61/1562), INL volume showed a sig-
nificant annualised increase of 0.01mm3 (p< .001).
In contrast, in eyes without MSON during the obser-
vation period, no significant annualised change in
INL was observed (b¼ –0.001mm3, p¼ .203,
Figure 2(b)). Exclusion of patients with a progres-
sive disease type, or adjustments for use of DMT,
disease duration or participating centre, did not
change these results (data not shown).
Table 2. Retinal layer thickness at baseline.
All eyes
N¼ 1570
MSON
before BL
N¼ 451
No MSON
before BL
N¼ 1119
HCs
N¼ 184
p valuea
MSON
vs HC
p valuea
No MSON
vs HCs
p valuea
No MSON
vs MSON
INL (mm3) 0.98 (0.08) 0.99 (0.08) 0.97 (0.08) 0.96 (0.09) .001 .066 .001
GCIPL (mm3) 1.79 (0.26) 1.62 (0.25) 1.86 (0.23) 1.97 (0.19) <.001 <.001 <.001
pRNFL (mm) 91.4 (15.8) 81.4 (17.5) 95.2 (13.2) 95.8 (9.1) <.001 .106 <.001
BL: baseline visit; HC: healthy controls; GCIPL: ganglion cell-inner plexiform layer; INL: inner nuclear layer; MSON: multiple sclerosis–
related optic neuritis; pRNFL: peripapillary retinal nerve fibre layer.
aGeneralised estimation equation analyses, unadjusted.
Figure 2. Relative change in retinal layer thickness with 95% confidence interval (based on generalised estimation equation model) for (a) all
multiple sclerosis (MS) and healthy control (HC) eyes and (b) stratified by multiple sclerosis optic neuritis (MSON).
GCIPL: ganglion cell-inner plexiform layer; INL: inner nuclear layer; pRNFL: peripapillary retinal nerve fibre layer.
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The annualised rate of change for GCIPL in MS
patients was –0.012mm3 (p< .001), which was sig-
nificantly more than observed in HCs (–0.004mm3,
p¼ 0.116, p value for comparison .008). The pRNFL
showed significantly more thinning in MS patients
(–0.97 mm, p< .001) compared with HCs (–0.42 mm,
p< .001, p value for comparison .001, Figure 2(a)).
For both layers, eyes with episodes of MSON during
the follow-up period showed significantly more thin-
ning than unaffected eyes (Figure 2(b)).
Short- and long-term effects of clinical disease
activity on retinal layer thickness
Table 3 demonstrates the effects of new episodes of
MSON during follow-up, other clinical relapses and
disease progression on annualised change in INL and
GCIPL volume and pRNFL thickness. The short-term
(clinical event and retinal change assessed within the
same follow-up period, Table 3(a)) as well as the
long-term (time-lag analyses, clinical event between
t0 and t1 and change in retinal layer thickness
between t1 and t2, Table 3(b)) effects are reported.
The median duration of t0–t1 was 1.1 year (IQR 1.0–
1.9) and for t1–t2 the median duration was 1.0 year
(IQR 1.0–1.7).
Clinical episodes of MSON during follow-up
demonstrated only a short-term effect on INL (thick-
ening) and GCIPL and pRNFL (thinning). In the
time-lag analyses investigating the long-term effects,
these effects disappeared. Exclusion of patients with
a progressive disease course did not change the sta-
tistical findings.
Clinical relapses (other than MSON) during follow-
up were present in 24.4% of patients. The occur-
rence of clinical relapses during the first follow-up
was not related to change in INL within the same
Table 3. (a) Short- and (b) long-term effects of MSON, clinical relapses (other than MSON) and disability
progression on annualised change in INL and GCIPL volume and pRNFL thickness.
(a) b (95% CI) short term p valuea
MSON (N¼ 26 eyes) vs no MSON (N¼ 1039 eyes)
INL 0.01 (0.006 to 0.020) <.001
GCIPL –0.13 (–0.18 to –0.08) <.001
pRNFL –7.61(–10.8 to –4.3) <.001
Relapse (N¼ 214 eyes) vs no relapse (N¼ 789 eyes)
INL 0.000 (–0.004 to 0.004) .868
GCIPL –0.10 (–0.18 to –0.002) .012
pRNFL –0.54 (–1.14 to 0.07) .082
Progression (N¼ 223 eyes) vs no progression (N¼ 673 eyes)
INL 0.001 (–0.004 to 0.005) .774
GCIPL 0.001 (–0.006 to 0.008) .764
pRNFL –0.13 (–0.66 to 0.41) .646
(b) b (95% CI) long term (time-lag model) p valuea
MSON (N¼ 11 eyes) vs no MSON (N¼ 581 eyes)
INL –0.006 (–0.026 to 0.013) .535
GCIPL 0.023 (–0.065 to 0.112) .604
pRNFL –1.124 (–3.78 to 1.53) .406
Relapse (N¼ 148 eyes) vs no relapse (N¼ 440 eyes)
INL 0.005 (0.001 to 0.01) .025
GCIPL –0.005 (–0.015 to 0.005) .307
pRNFL –0.40 (–1.57 to 0.77) .501
Progression (N¼ 97 eyes) vs no progression (N¼ 409 eyes)
INL 0.001 (–0.004 to 0.007) .609
GCIPL –0.006 (–0.02 to 0.006) .329
pRNFL –0.65 (–0.69 to 1.99) .342
b¼ regression coefficient; CI¼ confidence interval; HC: healthy controls; GCIPL: ganglion cell-inner plexiform
layer; INL: inner nuclear layer; MSON: multiple sclerosis–related optic neuritis; pRNFL: peripapillary retinal nerve
fibre layer.
aGeneralised estimation equation model adjusted for inter-eye dependency and baseline retinal thickness.
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period (median 1.1 years from baseline, b¼ 0.000,
95% confidence interval (CI) –0.004 to 0.004,
p¼ .868) but was significantly associated with an
increase in INL volume in the subsequent follow-
up (median 2.2 years from baseline, b¼ 0.005,
95% CI 0.001 to 0.01, p¼ .025). This effect was
similar when only patients with a relapsing disease
course were included (N¼ 508 eyes, b¼ 0.005
(95% CI 0.00 to 0.01, p¼ .049)). For GCIPL
volume and pRNFL thickness, this effect was more
pronounced in the short term (i.e. relapse and retinal
volume change within the same follow-up period,
Table 3(a)).
Disability progression was observed in 17.2%
(during the entire follow-up period). Annualised
change in INL volume was independent of disability
progression both in the short and long term.
Likewise, disability progression was not significant-
ly associated with annualised changes in GCIPL or
pRNFL (Table 3(a) and 3(b)).
Effect of MMO, disease type and DMT on
retinal changes
In the 1.4% of eyes with MMO before or during the
study (18/1275 eyes), the INL volume at the last visit
was 0.07mm3 higher compared with eyes without
MMO (p¼ .006, adjusted for new episodes of
MSON). Likewise, the average annualised rate of
change of INL volume was significantly higher in
eyes with MMO compared with eyes without
(b¼ 0.01, p¼ .011, adjusted for baseline INL and
episodes of MSON during follow-up), showing a
significant annualised increase over time in MMO
eyes (0.01 0.02mm3), but no change in eyes with-
out (–0.0002 0.02mm3).
Just more than half the patients (53.8%) used DMT
during the study. Although the annualised change in
INL volume was not influenced by use of DMT, the
absolute INL volume was significantly higher in
patients using fingolimod compared with RRMS
patients who did not use any DMT, independent of
history of pre-study MSON and MMO, EDSS at
baseline and disease duration (difference 0.03mm3,
p¼ .004). Other therapies did not show significant
differences in INL volume.
Interrelationship between layers
All analyses regarding the interrelationships between
the layers demonstrated effect modification by pres-
ence of a new episode ofMSON during follow-up and
are therefore stratified. In eyes with MSON during
follow-up, an increase in INL volume was related to
a decrease in GCIPL volume (standardised b¼ –0.42,
p¼ .006, black line in Supplementary Figure 1(a))
and to a lesser extent (although not statistically sig-
nificant) to a decrease in pRNFL (standardised
b¼ –0.15, p¼ .148, black line in Supplementary
Figure 1(b)). In eyes without new MSON, no signif-
icant association with change in INL volume was
observed (grey lines in Supplementary Figures 1(a)
and (b)). In contrast, GCIPL and pRNFL show posi-
tive correlations both in eyes with newMSON (stand-
ardised b¼ 0.41, p< .001) and without MSON
(standardised b¼ 0.26, p¼ .004, see Supplementary
Figure 1(c)).
Discussion
This longitudinal, multi-centre study demonstrates
that thickening of the INL as measured with
spectral-domain OCT reflects adjacent inflammation
of the optic nerve. Besides this association with local
inflammation, the INL seems to reflect some degree
of global disease activity, as the occurrence of clin-
ical relapses in any functional system was signifi-
cantly associated with a subsequent increase in INL
volume. However, this effect was relatively small
(difference of 0.005mm3) and should be interpreted
with caution, as the sensitivity might be limited.
These findings build on previous findings from other
studies, demonstrating the relationship between
thickening of the INL and physical disability9 and
disease activity.10 Saidha et al.10 reported that INL/
OPL thickening at baseline was predictive of clinical
relapses, new T2 and contrast-enhancing lesions on
magnetic resonance imaging and disability progres-
sion during follow-up. In contrast, in the present
study we did not observe any predictive value of
INL thickening on clinical relapses or disability pro-
gression. Our data demonstrated an association
between INL volume and clinical relapses only in
the time-lag model, in which clinical relapses pre-
ceded INL thickening. This would suggest that INL
thickening occurred subsequent to inflammatory dis-
ease activity. A predictive effect of baseline INL
volume on the occurrence of relapses or disability
progression, as described by Saidha and col-
leagues,10 was not observed in the present study.
When thickening of the INL was first described, it
was directly linked to the presence of MMO.9
Although MMO is present in MS and is related to
increased disability,9,10,18 it is not specific for MS
and may vary over time in individual patients.19,20
Importantly, we have previously demonstrated that
MMO was transient in 84% of cases.19 In the pre-
sent study, MMO was present in 2.4% of patients,
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which is consistent with previous findings.9–11,21 In
the present study we observed increased INL volume
in eyes with MMO, which is also consistent with
existing literature.1 Moreover, eyes with MMO
also showed a significant increase in INL volume
over time. Nevertheless, the findings of the present
study did not change when MMO eyes were exclud-
ed, suggesting that thickening of the INL can occur
in the absence of visually detectable MMO.
The underlying mechanism responsible for thicken-
ing of the INL remains unknown. The findings of
this study would imply that previously suggested
mechanisms such as inflammation-related dynamic
fluid shifts and Mu¨ller cell dysfunction are more
likely than other non-inflammatory mechanisms
such as traction and retrograde trans-synaptic degen-
eration.21,22 Dynamic retinal layer volume changes
can be explained by fluid shifts due to a combination
of osmotic and hydrostatic gradients, the retinal
glymphatic system.23–26 The INL is embedded
between the superficial vascular plexus and the
deep capillary plexus, which can be clearly visual-
ised on OCT angiography.24 Typically, fluid reaches
the retina through the internal limiting membrane
and both plexuses, whereas both plexuses and
Mu¨ller cells can absorb the interstitial fluid. In
case of inflammation, diffusion of fluid from the
retinal blood vessels increases, leading to an increase
in INL volume. Another suggested mechanism is
pathology of Mu¨ller cells, which would impair the
absorption of interstitial fluid, also resulting in
increased INL volume. Other suggested non-
inflammatory mechanisms such as traction or retro-
grade trans-synaptic degeneration are also plausible
but less well supported by our data, given the clear
and direct increase in INL volume following MSON.
One approach to further elucidate the underlying
mechanism would be the investigation of the retinal
vessels using OCT angiography.
Previously, we and others have described the limited
susceptibility of the INL to retrograde degeneration
caused by MSON.1 This is in line with our current
findings, in which the pRNFL and GCIPL clearly
showed significant thinning in eyes with previous
episodes of MSON, whereas for the INL no thinning
but rather an increase in volume was observed. The
opposing effects of local inflammation on the INL
on the one hand and pRNFL/GCIPL on the other are
clearly demonstrated by the negative correlation
between the layers. This further substantiates the
potential of pRNFL/GCIPL as a measure for
neurodegeneration, whereas INL volume may be a
valuable parameter for reflecting inflammato-
ry activity.
A recent study by Knier et al. reported that effective
treatment with DMT in patients with MS is associ-
ated with a sustained reduction in INL volume in the
absence of MSON, and they suggested that INL
volume may be a response marker for successful
treatment of inflammation.11 Building on these find-
ings, we investigated the effect of DMT on INL
volume changes. Although the absolute INL
volume was significantly higher in patients using
fingolimod compared with RRMS patients who did
not use any DMT, which corroborates previous find-
ings on retinal effects of this drug,27,28 the annual-
ised change in INL volume was not influenced by
use or type of DMT. However, it should be noted
that DMT data were available only at baseline for
the majority of patients, and that data on the exact
duration of treatment or previous DMTs were not
available. This lack of detailed information did not
permit a thorough investigation of direct effects of
DMT or replication of previous results.
Another limitation of the study was that the data did
not permit the determination of how acute new epi-
sodes of MSON were. A systematic assessment of
the early time course of acute MSON would be
extremely valuable, and there will need to be a con-
sensus as to what will be defined as onset of an acute
episode of MSON. Furthermore, disease activity was
recorded only by clinical relapse activity. Data on
radiological disease activity (new T2 and/or
gadolinium-enhancing lesions during follow-up)
were not available. Therefore, no conclusions
could be made regarding the relationship of INL
volume and radiological disease activity. A
common limitation of multi-centre studies is the dif-
ference in methodology among the participating
centres.29,30 The OCT device and software were
the same for all centres (Spectralis) but one
(Topcon). The data on retinal layer thickness of
this particular centre were not significantly different
from the other centres’, and additional adjustment
for a potential centre effect did not change any of
the results (data not shown).
In summary, our data demonstrate that an increase in
INL volume is strongly associated with inflamma-
tion of the optic nerve, and to a lesser degree with
other clinical relapses. Therefore, INL volume may
be a valuable parameter for capturing inflammatory
Multiple Sclerosis Journal—Experimental, Translational and Clinical
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disease activity and may be considered as an out-
come measure for MS and MSON treatment trials.
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